Antibiotics Are an Economic Failure (17 minute read)
Antibiotic resistance kills millions annually, but the real bottleneck isn't scientific discovery—it's that antibiotics are economically unviable for pharmaceutical companies to develop.
What: An analysis of why antibiotic development has stalled despite AI solving the discovery problem, focusing on market failures that make antibiotics unprofitable compared to chronic disease drugs and exploring policy solutions like subscription models and guaranteed payments.
Why it matters: This represents a critical market failure where capitalism's incentive structures actively work against solving a major public health crisis, illustrating how economic design can matter more than technological capability.
Deep dive
- Antibiotic resistance caused 4.95 million deaths in 2019 (more than HIV or malaria), yet AI models have "essentially solved" the molecular discovery problem according to researchers
- The crisis stems from two factors: social practices (agricultural overuse, over-the-counter availability in developing countries) and economic incentives that make antibiotic development unprofitable
- Developing a new antibiotic costs an estimated $2.6 billion but faces a catch-22: if reserved as last-resort treatment, few doses sell during the patent window; if widely prescribed, resistance develops quickly and sales drop
- Antibiotics are prescribed for days while chronic disease drugs generate revenue for years, and patents often expire before drugs transition from reserve to widespread use
- Of 38 major antibiotic groups known today, 28 were discovered between the 1940s and 1970s; modern pharmaceutical companies have largely abandoned the field
- "Push" incentives (government R&D funding like CARB-X) have failed to increase the pipeline, which has remained stuck in the low 40s since 2014
- Startup Achaogen's 2019 bankruptcy exemplified the problem: after $500 million in funding and FDA approval, their antibiotic generated only $800,000 in six months before collapse
- "Pull" incentives aim to guarantee returns: UK NHS pays £10 million annually for 10 years via subscription model; US PASTEUR Act (proposed 2020, still pending) would authorize $75-300 million annual subscriptions
- The EU approved 12-month patent extensions for new antimicrobials in late 2025, transferable to other drugs in a company's portfolio
- Gepotidacin's December 2025 FDA approval (first new gonorrhea antibiotic since 1987) succeeded due to resistance-averse dual-enzyme mechanism, clear market demand (300,000+ US gonorrhea cases annually), GSK retaining in-house expertise, and $200+ million in government funding
- The colistin case study shows how agricultural use undermines clinical antibiotics: banned from human use due to toxicity but used as livestock growth promoter until resistance genes (MRC-1) jumped to plasmids in 2015
- Market entry awards and advanced market commitments (which funded pneumococcal vaccines, saving 700,000 lives) are being considered but don't decouple profit from volume like subscriptions do
- Best near-term solution is stewardship: reducing agricultural antibiotic use, improving healthcare capacity in developing countries, and ensuring careful prescription practices
Decoder
- Push incentives: Government or nonprofit funding provided during R&D phase to reduce development costs and risk
- Pull incentives: Financial guarantees or rewards that activate when a drug reaches market, ensuring companies can recoup investment
- CARB-X: Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, a public-private partnership funding antibiotic development
- PASTEUR Act: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, proposed US legislation for subscription-based antibiotic purchases
- Plasmid: Circular DNA molecule separate from chromosomes that bacteria can exchange, enabling rapid spread of resistance genes
- Topoisomerase: Enzymes that manage DNA supercoiling during replication; gepotidacin requires mutations in two types simultaneously for resistance
- Advanced market commitment: Promise to purchase a specified quantity at a set price once a product is developed, de-risking R&D investment
- Market entry award: Lump-sum payment when a drug successfully reaches market, regardless of sales volume
- Patent exclusivity: Period during which only the patent holder can sell a drug before generic manufacturers can compete
Original article
The discovery of antibiotics enabled many of our modern medical procedures, including many routine surgeries and immunosuppressant treatments such as chemotherapy. Antibiotic resistance is considered to be one of the greatest public health threats to humanity. If a new antibiotic entered the market, it would either be used as a last line of defense, which means few doses would be sold, or it would be widely used until resistance developed again, after which sales would drop. Antibiotics are only used for a few days, so there's little profit potential. These factors mean there's less money in developing and selling antibiotics compared to drugs for chronic diseases.